US loses measles elimination status as Bristol Myers Squibb CEO warns science ecosystem is at risk

US loses measles elimination status as Bristol Myers Squibb CEO warns science ecosystem is at risk

On the day the United States officially lost its measles elimination status, Bristol Myers Squibb CEO Chris Boerner issued a warning that went beyond one disease. Speaking at the Fortune 500 Innovation Forum in Detroit on Nov. 17, 2026, he said America's lead in new medicines rests on a system that must be protected, and that the benefit is "not a birthright."

Key facts about the status loss

  • The Pan American Health Organization said Tuesday the U.S. no longer meets the measles elimination standard it first cleared in 2000: no single chain of measles transmission lasting 12 months or longer.
  • The CDC has counted more than 5,400 measles cases so far in 2026, up from 2,289 last year, according to CBS News. Many cases came from outbreaks that began in close-knit Mennonite communities and spread.
  • Mexico and Bolivia also lost their status this week. Canada lost it last year.
  • In the 2025-26 school year, 92.4% of U.S. kindergartners had their MMR shots, down from 95.2% before the pandemic, per CDC data. Vaccine exemptions hit a record 4.2%.
  • Epidemiologists say measles herd immunity, the point where spread slows because enough people are immune, requires about 95% coverage.

What the Bristol Myers CEO said

Boerner, who is board chair and CEO of Bristol Myers Squibb, said the U.S. leads the world in new medicines, with 90% of new drug launches happening in America, often two to three years before other wealthy countries get them. "That's a real benefit that we have, but it's not a birthright," he said.

He did not name Health Secretary Robert F. Kennedy Jr. or any specific policy. Instead, he listed what he believes keeps the U.S. ahead: a public-private partnership built around the NIH, a deep biotech scene, access to capital, drugmakers that work from discovery to sale, and "an FDA that's the sort of global standard." Under all of it, he said, sits "a respect for science."

"Whenever you undermine any piece of that ecosystem, it impacts the whole," he said. "If we want to continue to benefit from advanced therapies, including some of the world's best vaccines, I think we need to be mindful of improving that ecosystem and being very careful about policies that don't."

Pressed on how he felt personally about the status loss, he called it "clearly troubling."

How his comments compare with other drugmaker leaders

Boerner's restraint stands out against his peers. Pfizer CEO Albert Bourla told investors last December that "science is replaced with political beliefs" at the Department of Health and Human Services, according to BioSpace. At Davos in January, asked what stands in the way of a better vaccine conversation, Bourla answered: "The Secretary of Health."

The CDC's response

The CDC played down the designation. "The measles elimination designation is not what protects Americans. Vaccination does," CDC Director Dr. Erica Schwartz said in a statement Tuesday. She pointed to $100 million the agency has sent to state and local health departments.

Boerner's other comments on drug pricing and policy

Boerner also spoke about the cost of medicines. He said drugs are about 10% to 15% of U.S. health spending and have been for a decade, so "we got to bring the other 85% to the table." He said roughly 50 cents of every dollar spent on a branded drug goes to someone who had nothing to do with discovering or developing it, calling that inefficiency and borrowing the president's word, "middlemen."

He said Bristol Myers runs assistance programs for uninsured and underinsured patients but is "prohibited by statute" from offering them to people on Medicare. "That's unacceptable. We should fix that." He also said he would happily be paid more when a drug works and less when it does not, but U.S. rules make those deals hard, so the company does far more of them abroad.

In December 2025, Bristol Myers was one of nine drugmakers to sign most-favored-nation pricing deals with the White House. On Tuesday, Boerner credited President Trump with getting one thing "absolutely" right: other countries "are not paying their fair share." He pointed to the U.K.'s pledge, in its pharmaceutical trade deal with the U.S., to double its spending on innovative medicines over about a decade.

Changes inside Bristol Myers Squibb

Last week, the company said it will fold research and development into a single organization under chief medical officer Cristian Massacesi starting Jan. 1. Chief research officer Robert Plenge will leave after an advisory stint through March. Boerner said the traditional boundaries between research and development "are collapsing."

He told Fortune's Diane Brady that AI lets the company run in parallel work that used to happen in sequence. Bristol Myers has committed to cutting the time from a drug entering the clinic to approval by 30%. Boerner thinks AI "will beat that by a mile."

What happens next on measles

The Pan American Health Organization expects the U.S. to submit a plan in the coming weeks to stop measles transmission. Regaining the status means going at least a year without an unbroken chain of spread.

Boerner's advice went wider than one virus. "We've got to be mindful of the entire ecosystem," he said, "and treat it like an ecosystem."

Sources

Newisty Editorial Team
Written by

Newisty Editorial Team

Technology · Crypto · Digital Economy
View all posts

Newisty Editorial Team covers technology, cryptocurrency, digital products, online platforms, developer tools and the wider digital economy. Our content is researched from official sources, company announcements, public documentation, market data and other primary or reputable sources. Articles are reviewed and edited before publication for clarity, accuracy and useful context.

Comments (0)

Leave a comment
Your comment will appear publicly after submission.
No comments yet. Be the first to comment!